Enabling Precision Immunology

Founded by Longwood Fund, ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases. We are employing our massively parallel, multiplexed, and unbiased systems to develop therapeutics for autoimmunity, severe allergy, oncology and infectious disease.

Leadership

Management Team

Christoph Westphal, MD PhD
Executive Chair, ImmuneID Partner, Longwood Fund

David H. Donabedian, PhD MBA

Start-up CEO, ImmuneID
Annalisa D’Andrea PhD
CSO and President, ImmuneID
Jeff Capello, MBA
CFO/COO, ImmuneID
Thomas Haag, JD PhD

GC, ImmuneID

Lucy Liu, PhD

Head of Strategy, ImmuneID
Senior Associate
Longwood Fund

Lea Hachigian, PhD
BOD (Founding CEO) Principal, Longwood Fund

Ittai Harel, MBA

ImmuneID, BOD
Managing Partner, Pitango

Peter Hutt, JD

GC, ImmuneID BOD
Senior Counsel, Covington & Burling LLP

Advisors

Steve Elledge, PhD
Tomasz Kula, PhD
H. Benjamin Larman, PhD
Michael Mina, MD PhD
Kari Nadeau, MD PhD
Chris Walsh, PhD
David Walt PhD

News

Investors

Contact

650 East Kendall St, 2nd Floor
Cambridge, MA 02142

info@immuneidrx.com

©2021 ImmuneID, Inc.